Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

The Clorox Company (CLX) SEC Filings & Earnings Calls

EquiReason read 16 The Clorox Company SEC filings in the last 12 months. Latest: DEF 14A on 2026-10-07 — CEO announced stepping down for health reasons; CEO search initiated..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CLXThe Clorox CompanyFollow CLX — free
Household & Personal Products · Consumer Defensive
—
Price chart with a free account
Market cap
10.4B
P/E TTM
17.9
Dividend yield
5.7%
52-week
—
Next earnings
2 Nov, in 9 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

7 Oct 2026DEF 14ACEO announced stepping down for health reasons; CEO search initiated.open

Figures in the filing · each found in the filing text

Net Sales · FY2026$6.72B-5% y/y
Net Earnings Attributable to Clorox · FY2026$587M-28% y/y
Gross Margin · FY202642.3%
Dividends Paid · FY2026$602M
Employees · FY20269,200

Risks flagged

CEO succession risk

“In May 2026, the Company announced that Chair and CEO Linda Rendle had asked the Board of Directors (Board) to initiate a comprehensive CEO search process following her decision to step down for health reasons.” · word for word

Macroeconomic and consumer demand uncertainty

“Continued macroeconomic volatility and geopolitical instability, including shifts in U.S. and global trade policies, tariffs, ongoing conflicts in the Middle East and Ukraine, tensions involving the U.S. and Iran, and rising friction between China and Taiwan, have increased uncertainty around economic conditions, global trade, supply chains, and the duration” · word for word

ERP transition disruption

“The result reflected operational challenges early in the year associated with our U.S. ERP transition, the significant year-over-year impact of the related inventory drawdown, and lower-than-anticipated business performance in the second half amid slower category growth and increased competitive activity.” · word for word
Read the original on SEC EDGAR ↗
7 Aug 202610-KClorox reported a decline in net sales and a 26% decrease in EPS for fiscal year 2026, driven by ERP disruption and macroeconomic headwinds.earningsopen

Figures in the filing · each found in the filing text

Net sales · FY2026$6.70B
Diluted net earnings per share (EPS) change · FY2026-26.0%
Dividends paid · FY2026$602M
Dividend increase · FY20271.0%
Transformational investment · FY2022-FY2026$580M
Walmart sales concentration · FY202626.0%

Risks flagged

CEO succession risk

“In May 2026, the Company’s Chief Executive Officer and Chair Linda Rendle announced her planned resignation, and the Board has initiated a process to identify a successor.” · word for word

ERP integration disruption

“The ERP system implementation, which was completed in January 2026, has required, and will continue to require, investment of personnel and financial resources to support post-implementation efforts and system functionality.” · word for word

Customer concentration

“Net sales to the Company’s largest customer, Walmart Stores, Inc. and its affiliates, were 26%, 27% and 25% of consolidated net sales for the fiscal years ended June 30, 2026, 2025 and 2024, respectively” · word for word

Commodity cost volatility

“Volatility and increases in the cost of key raw materials and packaging inputs, including resins, non-woven fabrics for wipes products, chemicals, agricultural commodities and packaging materials, as well as energy, transportation, labor and other supply costs, have harmed, and may continue to harm, the Company’s results of operations.” · word for word
Read the original on SEC EDGAR ↗
3 Aug 20268-K · 2.02, 7.01Net Sales $1.95B (-2% y/y); Organic Sales Growth -13; Gross Margin 41.3earningsopen

Figures in the filing · each found in the filing text

Net Sales · Q4-2026$1.95B-2% y/y
Organic Sales Growth · Q4-2026-13.0%
Gross Margin · Q4-202641.3%
Diluted EPS · Q4-2026$1.34-50% y/y
Adjusted EPS · Q4-2026$1.66-42% y/y

Risks flagged

Continued cost volatility and value-seeking consumer expected to persist in FY27.

“As we begin fiscal year 2027, we expect the operating environment to remain challenging, with continued cost volatility and a value-seeking consumer.” · word for word
Read the original on SEC EDGAR ↗
17 Jun 20268-K · 5.02, 7.01Base salary (COO) $800,000.00; short-term incentive target (COO) 100; RSU grant value (COO) $4Mopen

Figures in the filing · each found in the filing text

base salary (COO) · point_in_time$800000.00
short-term incentive target (COO) · point_in_time100.0%
RSU grant value (COO) · point_in_time$4M

Risks flagged

CEO search ongoing; leadership transition risk.

“the Clorox Board of Directors is undertaking a comprehensive search with a leading firm to execute its search for a new CEO.” · word for word
Read the original on SEC EDGAR ↗
28 May 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open

Risks flagged

Leadership transition risk during CEO search; potential strategic uncertainty.

“CEO stepping down for health reasons; search process initiated; no successor named.”
Read the original on SEC EDGAR ↗
11 May 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen

Risks flagged

Increased leverage and interest expense from $1.5B debt issuance.

“Issuance of $1.5B in senior notes with coupons ranging from 4.700% to 5.250%.”
Read the original on SEC EDGAR ↗
30 Apr 202610-QNet Sales $1.67B (+0% y/y); Net Sales $4.77B (-7% y/y); Gross Margin 43.2open

Figures in the filing · each found in the filing text

Net Sales · Total Company · Q3-2026$1.67B0% y/y
Net Sales · Total Company · 9M-2026$4.77B-7% y/y
Gross Margin · Total Company · Q3-202643.2%
Gross Margin · Total Company · 9M-202642.7%
Diluted EPS · Total Company · Q3-2026$1.54+3% y/y
Diluted EPS · Total Company · 9M-2026$3.47-10% y/y
Segment Adjusted EBIT · Total Company · Q3-2026$296M+11% y/y
Segment Adjusted EBIT · Total Company · 9M-2026$712M-17% y/y
Operating Cash Flow · Total Company · 9M-2026$282M-59% y/y

Risks flagged

ERP Transition Disruption

“Volume decrease was primarily due to lower shipments in the current period following the incremental shipments related to the ERP transition in the fourth quarter of fiscal year 2025.” · word for word

GOJO Acquisition Integration Risk

“The risks arising from the integration of the GOJO business; the risk that the anticipated benefits and synergies of the acquisition may not be realized when expected or at all.” · word for word

Increased Leverage from Acquisitions

“As of March 31, 2026, the Company has issued approximately $1,591 of Notes and loans payable primarily comprised of U.S. commercial paper borrowings to finance the previously announced GOJO acquisition and fund the Venture Agreement termination payment.” · word for word
Read the original on SEC EDGAR ↗
30 Apr 20268-K · 2.02, 7.01Net Sales $1.67B (+0% y/y); Organic Sales Growth -1; Gross Margin 43.2; Guidance: Updated FY2026 outlook; GOJO acquisition adds 3 points to net sales, 2-4c dilution to adjusted EPS; ERP inventory drawdown reduces EPS by ~90cearningsopen

Figures in the filing · each found in the filing text

Net Sales · Q3-2026$1.67B0% y/y
Organic Sales Growth · Q3-2026-1.0%
Gross Margin · Q3-202643.2%
Diluted EPS · Q3-2026$1.54+3% y/y
Adjusted EPS · Q3-2026$1.64+13% y/y
Year-to-Date Net Cash Provided by Operations · FY2026$282M-59% y/y

Guidance

Updated FY2026 outlook; GOJO acquisition adds 3 points to net sales, 2-4c dilution to adjusted EPS; ERP inventory drawdown reduces EPS by ~90c

Updated outlook reflects mixed demand, margin pressure from costs, and transitory headwinds from ERP transition and GOJO acquisition.

Risks flagged

Gross margin pressure from manufacturing and logistics costs; operating cash flow down 59% due to Glad JV termination payment; consumer environment challenging.

“Gross margin decreased 140 basis points; Year-to-date net cash provided by operations was $282 million compared to $687 million; 'challenging consumer and cost environment'”
Read the original on SEC EDGAR ↗
1 Apr 20268-K · 7.01, 8.01Issued a Regulation FD disclosure (forward guidance or material update); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open

Risks flagged

Integration risk; potential unexpected costs or failure to realize synergies.

“risks arising from the integration of the GOJO business; risk that anticipated benefits and synergies may not be realized” · word for word
Read the original on SEC EDGAR ↗
10 Mar 20268-K · 1.01, 2.03Clorox entered $1B 364-day revolver and $1.25B delayed-draw term loan to finance GOJO acquisition; senior unsecured, interest coverage covenant only.open

Figures in the filing · each found in the filing text

364-Day Revolving Credit Facility · Q1-2026$1.00B
Delayed Draw Term Credit Facility · Q1-2026$1.25B

Risks flagged

Increased leverage from acquisition financing; interest coverage ratio covenant.

“Only financial covenant is consolidated interest coverage ratio; $2.25B in new debt.”
Read the original on SEC EDGAR ↗
3 Feb 20268-K · 2.02, 7.01Net sales $1.67B (-1% y/y); Organic sales growth -1; Gross margin 43.2; Guidance: Net sales down 6-10%, organic sales down 5-9%, gross margin down 50bpsearningsopen

Figures in the filing · each found in the filing text

Net sales · Q2-2026$1.67B-1% y/y
Organic sales growth · Q2-2026-1.0%
Gross margin · Q2-202643.2%
Diluted EPS · Q2-2026$1.29-16% y/y
Adjusted EPS · Q2-2026$1.39-10% y/y
Net cash provided by operations (YTD) · H1-2026$404M+1% y/y

Guidance

Net sales down 6-10%, organic sales down 5-9%, gross margin down 50bps

Reaffirmed FY2026 outlook but expects lower end of range due to order fulfillment challenges and inventory drawdown.

Risks flagged

Inventory drawdown from ERP transition expected to reduce FY2026 EPS by ~$0.90.

“Inventory draw down is expected to reduce fiscal year 2026 earnings per share by about 90 cents.” · word for word

Higher manufacturing and logistics costs pressuring margins.

“Gross margin decreased 60 basis points primarily due to higher manufacturing and logistics costs.”
Read the original on SEC EDGAR ↗
3 Feb 202610-QClorox reported H1 FY2026 net sales down 10% Y/Y and gross margin down 230bps, with significant volume declines across most segments.earningsopen

Figures in the filing · each found in the filing text

Net sales · Total Company · H1 FY2026$3.10B-10% y/y
Gross margin · Total Company · H1 FY202642.5%
Diluted net earnings per share · H1 FY2026$1.93-18% y/y
Segment adjusted EBIT - Household · Household · H1 FY2026$49M-55% y/y
Segment adjusted EBIT - Health and Wellness · Health and Wellness · H1 FY2026$314M-27% y/y
Segment adjusted EBIT - Lifestyle · Lifestyle · H1 FY2026$110M-19% y/y
Segment adjusted EBIT - International · International · H1 FY2026$50M-11% y/y
Operating cash flow · H1 FY2026$404M+1% y/y

Risks flagged

ERP transition disruption

“lower shipments in the current period following the incremental shipments related to the ERP transition in the fourth quarter of fiscal year 2025” · word for word

Leverage increase from acquisitions

“The pending acquisition of GOJO Industries announced on January 22, 2026 is planned to be funded primarily through debt financing.” · word for word

Glad venture buyout cash outflow

“the Company will purchase P&G’s 20% interest for $476, which is expected to be paid in cash during the third quarter of fiscal year 2026” · word for word
Read the original on SEC EDGAR ↗
22 Jan 20268-K · 7.01, 8.01Purchase price $2.25B; anticipated tax benefits $330M; Guidance: reaffirms fiscal year 2026 outlook for net sales, diluted EPS and adjusted EPSopen

Figures in the filing · each found in the filing text

purchase price · 2026-01-22$2.25B
anticipated tax benefits · 2026-01-22$330M

Guidance

reaffirms fiscal year 2026 outlook for net sales, diluted EPS and adjusted EPS

Reaffirmed FY2026 outlook; acquisition expected to be accretive with margin expansion and synergies.

Risks flagged

Debt financing increases leverage; integration risk; regulatory approval required.

“Clorox plans to fund the transaction primarily through debt financing. The transaction is subject to regulatory approval and other customary closing conditions.” · word for word
Read the original on SEC EDGAR ↗
3 Nov 202510-QClorox reported a 19% decline in net sales and a 410 bps gross margin contraction, driven by ERP transition shipment timing and higher costs.open

Figures in the filing · each found in the filing text

Net sales · Q1-2026$1.43B-19% y/y
Gross margin · Q1-202641.7%
Organic sales growth (decrease) · Q1-2026-17.0%
Net cash provided by operations · Q1-2026$93M-58% y/y
Segment adjusted EBIT - Health and Wellness · Health and Wellness · Q1-2026$124M-47% y/y

Risks flagged

ERP transition disruption

“Net sales and volume in the current period decreased by 19% and 18%, respectively, driven by lower shipments in the current period following the incremental shipments related to the ERP transition in the fourth quarter of fiscal year 2025.” · word for word

Glad venture terminal obligation

“As of September 30, 2025 and June 30, 2025 the estimated fair value of P&G’s interest in the venture was $476, of which $488 and $501, respectively, was recognized and reflected in Accounts payable and accrued liabilities.” · word for word

Tariff and trade policy risk

“United States trade policies continue to evolve, including new or increased tariffs on product imports from certain countries.” · word for word
Read the original on SEC EDGAR ↗
3 Nov 20258-K · 2.02, 7.01Net sales $1.43B (-19% y/y); Organic sales growth -17; Gross margin 41.7earningsopen

Figures in the filing · each found in the filing text

Net sales · Q1-2026$1.43B-19% y/y
Organic sales growth · Q1-2026-17.0%
Gross margin · Q1-202641.7%
Diluted net earnings per share · Q1-2026$0.65-19% y/y
Adjusted EPS · Q1-2026$0.85-54% y/y
Net cash provided by operations · Q1-2026$93M-58% y/y

Risks flagged

ERP transition causing significant sales and earnings disruption; inventory drawdown expected to reduce FY2026 EPS by ~90 cents.

“Sales -19%; adjusted EPS -54%; ERP impact ~7.5 points of sales decline; EPS reduction ~90 cents.”

Gross margin compression from lower volume and higher manufacturing/logistics costs.

“Gross margin -410 bps; higher manufacturing and logistics costs.”
Read the original on SEC EDGAR ↗
30 Oct 20258-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open

Risks flagged

Loss of senior operating and strategy executive with 27 years tenure

“Eric Reynolds, Executive Vice President – Chief Operating and Strategy Officer...following 27 years of service” · word for word

No replacement planned may indicate organizational flattening or restructuring

“The Company does not expect to appoint a replacement for Mr. Reynolds” · word for word
Read the original on SEC EDGAR ↗

The Clorox Company — questions

What did The Clorox Company file recently?
16 SEC filings in the last 12 months. Latest: DEF 14A on 2026-10-07 — CEO announced stepping down for health reasons; CEO search initiated.

Every figure on this page comes from The Clorox Company's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.